70
Participants
Start Date
September 7, 2022
Primary Completion Date
December 19, 2022
Study Completion Date
December 19, 2022
Infectious Titre 1
Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
Infectious Titre 2
Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
Infectious Titre 3
To be determined (TBD), depending on outcome of Part A
Infectious Titre 4
TBD, depending on outcome of Part A
hVIVO Services Ltd, London